Aspire Biopharma Holdings, Inc. (ASBP) Stock Price & Analysis
Aspire Biopharma Holdings, Inc. (ASBP) — MoonshotScore 23/100 (Weak band), calculated Nov 18, 2026. Price $7.65 (-3.04%), as of the Nov 19, 2026 trading session.
Educational signal · not a buy or sell recommendation · How to read this
Aspire Biopharma Holdings, Inc. · ASBP · NASDAQ
Aspire Biopharma Holdings, Inc. is an early-stage biopharmaceutical company focused on developing and marketing novel sublingual delivery mechanisms. Their lead product, Instaprin, aims to address cardiology emergencies and pain management through a fast-acting, soluble aspirin formulation.
Price as of Nov 19, 2026
Key Statistics
MoonshotScore v2 · Aspire Biopharma Holdings (ASBP)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
A strong balance sheet, but bottom-tier quality and an expensive valuation. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone and losses on top of negative retained earnings. Business Quality: Poor; Financial Safety: Fortress; Valuation: Rich; Growth Durability: Flat; Momentum: Quiet.
- quarterly revenue $63,103 (Q2 FY2026, quarter ended Jun 30, 2026)
- Altman Z -3.47 · Piotroski F 5
Holding back: weak fundamentals
Helping: balance-sheet strength
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 21 | Weak | |
| 21 | Weak | |
| 21 | Weak | |
| 21 | Weak | |
| 23 | Weak | |
| 23 | Weak |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $7.65 | |
| Change on the day | -3.04% | |
| 52-week range | $0.11 – $205.20 | |
| Price / earnings (trailing) | -0.10 | |
| Shares traded on the day | 9.7K |
Price & events
Other perspectives
Council score for Aspire Biopharma Holdings (ASBP): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
6 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 9, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Apr 29, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Apr 29, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Aspire Biopharma Holdings (ASBP), and what does it report?
Short answer · as of
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Aspire Biopharma Holdings, Inc. (ASBP) is listed on NASDAQ. It employs 2 people and is led by Kraig T. Higginson. In Q2 FY2026 it reported revenue of $63,103 and net income of -$1M.
What do the latest results show for Aspire Biopharma Holdings (ASBP)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of $63,103.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $63,103 | -$1M | -$1.22 (diluted) |
| Q1 FY2026 | $28,353 | -$3M | -$2.16 (diluted) |
| Q4 FY2025 | $4,261 | -$5M | -$3.15 (diluted) |
| Q3 FY2025 | $1,941 | -$2M | -$1.49 (diluted) |
What are the financial strengths and risks for Aspire Biopharma Holdings (ASBP)?
Short answer · as of
The MoonshotScore pillars rate balance-sheet strength as strengths. What is holding it back is weak fundamentals. The distress and quality screens read Altman Z -3.47 · Piotroski F 5. Trailing ratios: ROA -81.6% · current ratio 7.99 · earnings yield -126.6%.
How does Aspire Biopharma Holdings compare with its peers?
Short answer
Aspire Biopharma Holdings's score ranks 10th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $403.60 Nov 18, 2026 | $46.1B | 96 5-pillar Nov 18, 2026 | |
| $9.07 Nov 19, 2026 | $589M | 51 5-pillar Nov 18, 2026 | |
| $24.30 Nov 19, 2026 | $1.50B | 50 5-pillar Nov 18, 2026 | |
| $2.51 Nov 19, 2026 | $22.1M | 40 5-pillar Nov 18, 2026 | |
| $2.29 Nov 19, 2026 | $204M | 36 5-pillar Nov 18, 2026 | |
| $5.80 Nov 19, 2026 | $123M | 32 5-pillar Nov 18, 2026 | |
| $1.83 Nov 19, 2026 | $7.41M | 32 5-pillar Nov 18, 2026 | |
| $0.37 Nov 19, 2026 | $31.7M | 30 5-pillar Nov 18, 2026 | |
| $0.90 Nov 18, 2026 | $20.0M | 29 5-pillar Nov 18, 2026 | |
| Aspire Biopharma Holdings (ASBP) — this page | $7.65 | — | 23 |
| $18.75 Nov 19, 2026 | $133M | 22 5-pillar Nov 18, 2026 | |
| $1.61 Nov 19, 2026 | $57.9M | 21 5-pillar Nov 18, 2026 | |
| $2.28 Nov 18, 2026 | $12.3M | 21 5-pillar Nov 18, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held ASBP in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported ASBP in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
Investor Questions: ASBP Stock
These answers are editorial: 1 of these 9 answers is drawn from the ASBP research dossier (written May 10, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.
What does the MoonshotScore mean for ASBP?
ASBP carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. Aspire Biopharma Holdings, Inc. is an early-stage biopharmaceutical company focused on developing and marketing novel sublingual delivery mechanisms.
Is ASBP a good stock to buy?
Stock Expert AI does not rate ASBP buy, sell or hold. Aspire Biopharma Holdings, Inc. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the ASBP stock price today?
The last price recorded for Aspire Biopharma Holdings, Inc. (ASBP), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What are the main risks for ASBP?
Aspire Biopharma Holdings, Inc. faces several key risks, including regulatory hurdles, competition, and financial constraints. The company's success depends on obtaining regulatory approvals for its sublingual drug formulations, which can be a lengthy and uncertain process.
What are the key factors to evaluate for ASBP?
Aspire Biopharma Holdings, Inc. (ASBP) holds a MoonshotScore in the low range. This could provide access to additional funding, resources, and market expertise. Not financial advice.
How frequently does ASBP data refresh on this page?
ASBP's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven ASBP's recent stock price performance?
Aspire Biopharma Holdings, Inc. (ASBP) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Novel sublingual drug delivery technology. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ASBP overvalued or undervalued right now?
Aspire Biopharma Holdings, Inc. (ASBP) is loss-making, so its trailing P/E (listed under Price & valuation) is negative and not usable for valuation — lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of ASBP?
Fractional-share availability for Aspire Biopharma Holdings, Inc. (ASBP) depends on your brokerage, account and supported securities. Check the broker's current eligibility, minimums and fees before placing an order.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 10, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 14 figures on this page — 8 from Financial Modeling Prep (FMP), 5 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com